Skip to main content
PIII logo

PIII · P3 Health Partners Inc.

Track PIII — free
$2.70 -0.05 (-1.82%) At close · Nov 13
Market Cap
$19.61M
Shares
7.26M
Volume · Nov 13 29.47K Avg daily vol (3M) 30.21K

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$2.70 Open$2.77 Day$2.51–2.81 52W close$1.52–16.47 Avg vol 30d44K Short int14K · 0.2% of shares · 1.0d Short vol24% Last earningsNov 9, 2026 DataApr 2021–Nov 2026 Filing10-Q · Nov 9

Up next

Feb 8, 2027 Est · unconfirmed · in 12 wks

Latest documents

2026
Nov 9
Earnings call
Adjusted EBITDA midpoint raised to $100 million

P3 Health Partners reported Q3 adjusted EBITDA of $21 million and raised full-year 2026 guidance to $90 million to $110 million, with a $100 million midpoint, while year-to-date adjusted EBITDA reached $101 million.

4 source passages
Good day, and welcome to the P3 Health Partners 3rd Quarter 2026 Earnings Conference Call. Q3 marked our third consecutive profitable quarter. We delivered $21 million of adjusted EBITDA. On a year-to-date basis, adjusted EBITDA was $101 million, compared with adjusted EBITDA loss of approximately $85 million through the same period in 2025. We are raising the low end of our full year 2026 adjusted EBITDA guidance from $80 million to $90 million, resulting in a revised range of $90 million to $110 million and increasing the midpoint from $95 million to $100 million. Open the document at this passage
Nov 9
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue rose 15%, net income reached 30,777 (in thousands)

P3 Health Partners Inc. reported total operating revenue of 396,344 (in thousands), up 15%, and net income of 30,777 (in thousands) for the three months ended September 30, 2026.

Revenue $396.34M ▲ 14.8% Net income $15.62M Diluted EPS $0.07
Read from the MD&A section
5 source passages
P3 Health Partners Inc. | Q3 2026 Form 10-Q | 36 Comparison of the Three Months Ended September 30, 2026 and 2025 Total operating revenue | 396,344 | 100 | 345,253 | 100 Net income (loss) | 30,777 | 7 | (69,461) | (20) Total operating revenue | 396,344 | 345,253 | 51,091 | 15% Open the document at this passage
Nov 9
Current report 8-K
Adjusted EBITDA turns positive as guidance midpoint rises

P3 Health Partners reported third-quarter 2026 Adjusted EBITDA of $20.9 million and net income of $30.8 million, and raised its full-year 2026 Adjusted EBITDA guidance midpoint to $100 million.

Financial results
4 source passages
P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced its financial results for the third quarter ended September 30, 2026. Net income was $30.8 million compared to net loss of $69.5 million in the prior year quarter. Adjusted EBITDA(1) for the quarter was $20.9 million, or $66 PMPM, compared to a loss of $45.9 million, or negative $132 per-member-per-month in the prior year quarter. Full-year revised guidance reflects the increase to the low end of the Adjusted EBITDA range to $90 million, raising the midpoint to $100 million, based on underlying year-to-date performance, as well as the prior-year development and payer settlements recognized in the quarter. Open the document at this passage
Oct 15
Registration statement S-3
Registration statement

P3 Health Partners Inc. registered up to 15,636,134 Class A common shares for selling-stockholder resale after warrant exercises. It receives no resale proceeds but could receive approximately $167.9 million from cash exercises.

Read from the first part of this long document
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$1.55B
Trailing 12 months
Net income (TTM)
−$51.23M
Trailing 12 months
Revenue growth YoY
+14.8%
Year over year
Operating margin
-5.2%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$77.86M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+102.8%
Year over year · more shares
Price change (1Y)
-61.4%
Trailing year
Short interest
0.2%
Latest settlement · 1.0 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −59%
below
Price vs 50-day avg −51%
below
RSI (14) 28
oversold
MACD trend Negative
52-week position 8%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −35%
trailing
6-month return −79%
trailing
YTD return −23%
this year
Relative strength −80%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $6 › 200d $7 — 200d above 50d
Institutional flow Accumulating
26 of 34 funds reported for Sep 30 · net +1.2M sh shares · +6 new
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.19% of shares out · ▲ +21.0% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
34 holders — mid 3-yr range
Squeeze score 35
low risk · 0–100
Fundamentals
Weak
Revenue growth −3%
Y/Y
EPS growth +16%
Y/Y
Free cash flow $-91.2M
Balance sheet $248.4M
net debt
Quant / Vol
risk profile
Very High
Volatility 222%
annualized · 1-yr
Max drawdown −84%
past year
ATR 18.8%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 3 of last 3
Latest guidance · from the 8-K filed Nov 9, 2026
Medical Margin(1)(3) PMPM · Year Ending December 31, 2026 Non-GAAP Maintained $210 – $240
Aug 10, 2026 $210 – $240 changed to Nov 9, 2026 $210 – $240
Previous outlook earlier release · from the Earnings Call filed Aug 10, 2026

Still-open targets the latest release did not restate under the same label.

Adjusted EBITDA · full-year 2026 $80M – $110M
Guided vs delivered · last 3 settled
Total Revenues full year 2024
guided $1.45B – $1.55B
$1.5B In line
Revenue 2023
guided $1.2B – $1.25B
$1.27B Beat +3.4%
Revenue full-year 2022
guided $1.03B – $1.08B
$1.05B In line

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−59% Bearish
Price vs 50-day avg
−51% Bearish
RSI (14)
28 Neutral
MACD trend
Negative Bearish
52-week position
8% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $6 › 200d $7 — 200d above 50d
Institutional flow Accumulating
26 of 34 funds reported for Sep 30 · net +1.2M sh shares · +6 new
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.19% of shares out · ▲ +21.0% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
34 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $2 Now $3 · 8% Range high $16
vs 200-day avg -59% vs 50-day avg -51%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adjusted EBITDA (loss) non-GAAP 80.2M Six Months Ended June 30 —
Adjusted EBITDA (loss) PMPM non-GAAP $127 Six Months Ended June 30 —
Adjusted EBITDA PMPM non-GAAP $173 Q2 2026 —
Adjusted operating expense non-GAAP 56.25M Six Months Ended June 30 —
At-risk members 105,000 Q2 2026 —
Average at-risk members 104,800 the three months ended June 30, 2026 filing —
Medical margin non-GAAP 171.46M Six Months Ended June 30 —
Medical margin PMPM non-GAAP $271 Six Months Ended June 30 —
Platform support costs $26.97M the three months ended June 30, 2026 filing —
Platform support costs as % of total operating revenue 7% the three months ended June 30, 2026 filing —
Total lives under management 133,000 Q2 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Care Facilities — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
PIII
P3 Health Partners Inc.
this stock
$19.61M -22.6% -2.8% — 0.2%
HCA
HCA Healthcare, Inc.
$104.25B +6.9% +7.1% 16.6 2.3%
FSNUY
Fresenius SE & Co. KGaA
$33.34B +3.3% — — 0.0%
THC
Tenet Healthcare Corp
$22.76B +43.9% +0.9% 8.3 2.2%
EHC
Encompass Health Corp
$13.83B +32.8% +10.5% 22.0 3.7%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
38
% held
81.5%
Reported
26 of 34
Top holder
LMR Partners LLP
Held Float
View
Held by Funds
Fund positions
9
View
Short & Settlement
Short Interest Rising
Shares short
13.7K
Days to cover
1.0d
Change
+2.4K sh
View
Short Volume
Short vol %
24%
As of
Nov 13, 2026
Short Total
View
Fails to Deliver
FTD shares
1.3K
Value
$9.1K
As of
Sep 25, 2026
View
Off-Exchange
Off-exchange %
42.3%
Week of
Oct 5, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$1.5B
Net income (FY)
$-147.9M
EPS diluted
$-45.26
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 9, 2026
This year
20

P3 Health Partners Inc. reported total operating revenue of 396,344 (in thousands), up 15%, and net income of 30,777 (in thousands) for the three months ended September 30, 2026.

View
Earnings & Events
Webcasts
Last webcast
Nov 9, 2026
View
Investor Relations
Latest news
P3 Health Partners Announces Thir…
Published
Nov 9, 2026
View

Performance

5D 20D 120D MTD YTD
PIII -32.5% -34.8% -79.2% -33.0% -22.6%
SPY +2.6% -1.2% +0.5% -0.2% +10.6%
vs SPY -35.1% -33.6% -79.7% -32.8% -33.3%
Key facts CIK 1832511 CUSIP 744413204 13F (30d) 27 filings 17 filers Visit website Investor relations